EUVIMEDEUVIMED entdecken
Crossref

Development of a liquid chromatography-based versatile bioanalysis for bevacizumab based on pretreatment combining aptamer affinity purification and centrifugal ultrafiltration concentration

Kenichiro Todoroki, Daichi Hamada, Tomohiro Yamada, Taro Saito, Yutaka Shimizu, Eiji Sugiyama, Hajime Mizuno, Hideki Hayashi, Kaori Tsukakoshi, Kazunori Ikebukuro

Analytical Sciences · 2023

DOI: 10.1007/s44211-023-00417-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Analytical Sciences, 2023. Verfasst von Kenichiro Todoroki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Analytical and Bioanalytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-Ku, Shizuoka, 422…. Hauptthemen laut MEDLINE: Bevacizumab, Aptamers, Nucleotide. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Daiichi-Sankyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We report on the development of a versatile and accurate bioanalytical method for bevacizumab using a pretreatment method combining affinity purification with anti-idiotypic DNA aptamers and centrifugal ultrafiltration concentration, followed by liquid chromatography (LC)-fluorescence analysis. An affinity purification method using Sepharose beads as an affinity support removed immunoglobulin G and a large amount of coexisting substances in the serum sample. Purified bevacizumab was separated as a single peak by conventional LC and detected fluorometrically, showing good linearity (R2 = 0.999) in the range of 5-200 μg/mL, sufficient to analyze bevacizumab concentrations in the blood of bevacizumab-treated patients. By combining this purification method with a concentration method using a centrifugal filtration device that inhibits non-specific adsorption of bevacizumab, the quantitative range was reduced by a factor of 10 while showing good linearity (R2 = 0.999) in the 0.5-20 μg/mL range. The developed analytical method is expected to be used not only for general bioanalysis of therapeutic mAbs in clinical settings, but also for next-generation antibody drugs that show drug efficacy at low concentrations and for analysis of trace samples.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BevacizumabAptamers, NucleotideUltrafiltrationHumansChromatography, LiquidCentrifugationChromatography, Affinity

Stichwörter der Autor:innen

Aptamer affinity purificationBevacizumabBioanalysisLiquid chromatography

Substanzen

BevacizumabAptamers, Nucleotide

Autor:innen und Institutionen

  • Department of Analytical and Bioanalytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-Ku, Shizuoka, 422-8526, Japan. todoroki@u-shizuoka-ken.ac.jp.
  • Department of Analytical and Bioanalytical Chemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1, Yada, Suruga-Ku, Shizuoka, 422-8526, Japan.
  • Department of Biotechnology and Life Science, Tokyo University of Agriculture and Technology, 2-24-16 Naka-Cho, Koganei, Japan.
  • Laboratory of Analytical Chemistry, Faculty of Pharmacy, Meijo University, 150 Yagotoyama, Tempaku, Nagoya, 468-8503, Japan.
  • Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, Daigaku-Nishi 1-25-4, Gifu, 501-1196, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Daiichi-Sankyo

Zitieren

APA

Todoroki, K., Hamada, D., Yamada, T., Saito, T., Shimizu, Y., Sugiyama, E., Mizuno, H., Hayashi, H., Tsukakoshi, K., & Ikebukuro, K. (2023). Development of a liquid chromatography-based versatile bioanalysis for bevacizumab based on pretreatment combining aptamer affinity purification and centrifugal ultrafiltration concentration. Analytical Sciences. https://doi.org/10.1007/s44211-023-00417-2

Vancouver

Todoroki K, Hamada D, Yamada T, Saito T, Shimizu Y, Sugiyama E, et al. Development of a liquid chromatography-based versatile bioanalysis for bevacizumab based on pretreatment combining aptamer affinity purification and centrifugal ultrafiltration concentration. Analytical Sciences. 2023. doi:10.1007/s44211-023-00417-2

BibTeX
@article{Todoroki2023,
  author = {Todoroki, Kenichiro and Hamada, Daichi and Yamada, Tomohiro and Saito, Taro and Shimizu, Yutaka and Sugiyama, Eiji and Mizuno, Hajime and Hayashi, Hideki and Tsukakoshi, Kaori and Ikebukuro, Kazunori},
  title = {Development of a liquid chromatography-based versatile bioanalysis for bevacizumab based on pretreatment combining aptamer affinity purification and centrifugal ultrafiltration concentration},
  journal = {Analytical Sciences},
  year = {2023},
  doi = {10.1007/s44211-023-00417-2}
}
Kostenlos starten →